



CREO
MEDICAL

BRINGING ADVANCED ENERGY TO ENDOSCOPY

**Growth and
Innovation Forum
11 February 2020**

DISCLAIMER

IMPORTANT NOTICE

This presentation comprises the written materials/slides for a presentation concerning Creo Medical Group PLC (the “Company”). By reviewing this presentation you agree to be bound by the conditions set out below.

No reliance may be placed for any purposes whatsoever on the information in this presentation or on its completeness. The presentation is intended to provide a general overview of the Company’s business and does not purport to deal with all aspects and details regarding the Company. Accordingly, neither the Company nor any of its respective directors, officers, employees or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance may be placed on, the fairness, accuracy or completeness of the information contained in the presentation or of the views given or implied.

Neither the Company nor any of its respective directors, officers, employees or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

Certain statements in this presentation regarding the Company are or may be forward-looking statements. These forward-looking statements are neither historical facts or guarantees of future performance. Such statements are based on current expectations and belief and, by their nature, are subject to a number of known and unknown risks and uncertainties which may cause the actual results, prospects and developments of the Company to differ materially from those expressed or implied by these forward-looking statements.

The information contained in this presentation is for background purposes only.

The subject matter of the presentation may be subject to change and the Company does not take any responsibility for updating or amending the contents to reflect such changes. The material contained in this presentation reflects current legislation and the business and financial affairs of the Company which are subject to change without notice and audit and is subject to the provisions contained within legislation.

This presentation summarises information presented. Without prejudice to the generality of these conditions, this summary information, including any views given or implied, or any statement made, in relation to such information should not be relied upon, nor should it be treated as accurate or complete. This presentation and all such information contained herein should be read subject to the Company's latest interim results.

The information contained in this presentation has been obtained from Company sources and from sources which the Company believes to be reliable but it has not independently verified such information and does not guarantee that it is accurate or complete.

No statement in this presentation is intended to be a profit forecast and no statement in this presentation should be interpreted to mean that earnings per Company share for current or future financial years would necessarily match or exceed the historical published earnings per Company share.

OVERVIEW



Focused on the Emerging Field of Surgical Endoscopy to perform clinical procedures minimally and non-invasively

Creo Medical utilises **patented technology** combining microwave and bi-polar radio frequency energy via its CROMA Advanced Energy platform

Enabling a range of **miniature endoscopic devices** with precise cut, coagulation and ablation capability to treat as many conditions as possible

Aiming to exploit a **Paradigm Shift** in endoscopic surgery

Saves time and cost as both procedure time and hospital stay are reduced vs alternatives

Potential to Change the Treatment Pathway due to less risk of infection, ability to treat conditions what are currently untreatable and moves operating room treatment to outpatient treatment

The overall aim:

Significantly Improved Patient Outcomes!



UNIQUE POSITION THAT HAS BEEN DEVELOPED

Creo delivers **advanced Bi-polar RF and Microwave energy** into tiny devices that enable minimally invasive endoscopic and laparoscopic procedures

Combined **Bi-polar RF** and **Microwave advanced energy generator** – delivered through a **single port** into a suite of **multi and single modality**, matched devices:

- **the smallest** flexible **microwave ablation needle** in the world*
- **the only Bi-polar flexible RF vessel sealer** in the world*
- **the only Bi-polar RF blade** in existence in the world*
- **the only non-stick, microwave haemostasis device** in the world*



Utilising **higher frequency microwave energy** that provides **the most accurate** haemostasis and ablation*

All based on **Heavily Patented** developed **Platform Technology**

*These statements are made based on "expert market knowledge".

CROMA ADVANCED ENERGY PLATFORM

Platform Technology

176 Worldwide patents granted, **88** patent families and **567** patents pending¹



Game changing technology

- ☒ Bi-polar RF for precise localised cutting
- ☒ Microwave coagulation provides control
- ☒ Single interface port, no need to swap instruments
- ☒ Small integrated unit

Matched energy and device performance, ultimately providing a toolbox of energy-optimised devices

Dissection & Resection

Haemostasis

Ablation



* -Internal nomenclature

RESECTION AND HAEMOSTASIS DEVICES

“.... your device is like a harmonic scalpel at the end of a scope, this is the holy grail of therapeutic endoscopy!.”

Dr Rob Hawes MD

Florida Hospital, Orlando Center for Interventional Endoscopy

“Speedboat RS2 would transform my repertoire”

Mr Mike Williamson

Endoscopist, Royal United Hospital Bath

“....a great start point for the new user and a fundamental tool for the experienced operators”

Dr. Zacharias P. Tsiamoulos MBBS, PHD

Endoscopy Clinical Lead, GI Endoscopy East Kent University Hospitals Trust, Honorary Consultant in Endoscopy St Mark's Hospital/Academic Institute

Bi-Polar RF and Microwave resection and haemostasis devices:

Resector (Bi-polar RF and MW)



Speedboat® (Bi-polar RF and MW)



Haemostasis probe (non-stick MW)



Dr. Zacharias P. Tsiamoulos MBBS, PHD

Endoscopy Clinical Lead, GI Endoscopy East Kent University Hospitals Trust, Honorary Consultant in Endoscopy St Mark's Hospital/Academic Institute

Dr. Zacharias Tsiamoulos is a pre-eminent consultant within his field. He has a vast knowledge and passion for his work and is held in very high regard by his peers. He is currently the endoscopy clinical lead at East Kent Hospitals University NHS Foundation Trust.

SPEEDBOAT

"You don't have to be an expert to use Speedboat"

Dr Francisco Jose García Fernández,
Spain

COLORECTAL CANCER WORLDWIDE:

16m screening colonoscopies are performed per annum in the US¹

1.1m will find a lesion which should be treated²

Approximately **50%** of those lesions are surgically removed¹

But traditional colorectal surgery is associated with a **6%** mortality rate at 30 days³


3 **MICROWAVE COAGULATION**
controlled haemostasis

1 **INTEGRATED INJECTION NEEDLE**
no instrument exchange required

5 **ROTATION**
orientation in any plane

4 **PROTECTIVE HULL**
reduces risk of muscle damage

2 **BIPOLAR ELECTRODES**
precise lateral and forward dissection



1. US surgical procedure volumes 2010, Millennium Research, RPUS43SV10, February 2010
2. Gastrointest Endosc 2014;80-133-43
3. Ann R Coll Surg Engl 2011; 93: 445-450

:

Age:

B.:

07/2018


5:22

1

/---

0 Ce:0

ment:



THE ALTERNATIVE

- Up to 30cm of bowel removed and the two sections re-joined
 - Change to the anatomy of the patient – never the same again in terms of function
 - Potential stoma bag for up to 6 months or even life
 - Other associated effects such as depression
- Some patients may not tolerate surgery
- Typically between 3-4 hours of treatment under general anesthetic with associated risks
- Potentially up to 5 days hospital stay
- In one day, 3 patients treated under sedation with Speedboat® saved ~12 hours of operating theatre time and up to 15 inpatient days



Resector





Haemostasis probe

MICROWAVE ABLATION DEVICES

“.... anyone with Endoscopic Ultrasound training will be able to use this device.”

Dr Shyam Varadarajulu MD

Medical Director of AdventHealth Orlando Center for Interventional Endoscopy

“.... Can you imagine the utility of this? If we can navigate to lesions, sample them, but also ablate them all in one go? I think that will be completely revolutionary for lung cancer management”

Dr Pallav Shah

Consultant Pulmonologist Royal Brompton Hospital, UK /Academic Institute

Liver Cancer - is the **4th** biggest cause of cancer related deaths worldwide with **~780,000** deaths annually.

Pancreatic Cancer - during 2019 an estimated **56,000** Americans will be diagnosed with pancreatic cancer in the U.S., and some **45,750** are expected die.

Highest mortality rate of all major cancers. **91%** of pancreatic cancer patients will die within five years of diagnosis – only **9%** will survive more than five years. **74%** of patients die within the first year of diagnosis.

Kidney Cancer is increasing at one of the highest rates globally (est. **22% growth** 2014-2020) with over **400,000** instances per year.

Narrow Soft Tissue Ablation Device:



Flexible Ablation Device:



1. WHO, IARC Cancer Today Online Analysis 2018.
2. <https://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html>.
3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546485/>
4. European Association of Urology, Scientific & Policy Briefing on Kidney Cancer.

Shyam Varadarajulu

Medical Director, Center for Interventional Endoscopy Florida Hospital, Orlando, Florida

Dr. Varadarajulu performs approximately 2,500 EUS procedures per year. He specializes in the treatment of complex pancreatic and biliary disorders with particular expertise in Endoscopic Ultrasound and Therapeutic ERCP. Dr. Varadarajulu currently serves as Medical Director of CIE and Professor of Medicine at the University of Central Florida. He has authored more than 165 professional articles, 20 textbook chapters, and is the editor of the textbook, Endosonography.



Narrow Soft Tissue Ablation Device

1

2

3

4

5

6

7

8

9

10

11

12



Flexible Ablation Device



CONCLUSION

- **Creo's CROMA Advanced Energy platform** and product development enables a **Razorblade model** - with multiple devices over multiple markets and multiple indications
- Continue to drive Creo's **Clinical Education Programme** and establish **Training Centre's of Excellence** in core markets
- Focus on advancing the numbers of **Power Users** in key countries, initially focusing on US
- **Manufacturing capability** established and positioned to **scale**
- **On track** to accelerate roll out of products, increased training and market seeding via **multiple distribution partners**, and **further regulatory clearances**
- Recent fundraise of ~£52m enables Creo to **accelerate commercialisation in US and Europe**
- **Innovation remains at the heart of Creo**



ANYTHING IS
POSSIBLE WITH THE
RIGHT APPROACH